Nanobiotix announces the launch of a global offering of $30 million (€28.4 million), in the United States in the form of American Depositary Receipts (ADS), and in Europe, to qualified investors.

This fundraising will be completed by a private placement, reserved for Johnson & Johnson, the French biotech company's industrial partner, for an amount of $25 million.

'Nanobiotix shares will be suspended from trading on Euronext this November 2 until the opening of trading of Nanobiotix ADSs on Nasdaq, at around 2:30 pm (Paris time)', says the company.

Copyright (c) 2023 CercleFinance.com. All rights reserved.